Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 37 (1) , 34-37
- https://doi.org/10.1016/0026-0495(88)90026-1
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363, 586) in insulin-dependent diabetes mellitusLife Sciences, 1986
- Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSIIDiabetes, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- Glucose Counterregulation, Hypoglycemia, and Intensive Insulin Therapy in Diabetes MellitusNew England Journal of Medicine, 1985
- Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1985
- The “Dawn Phenomenon” — A Common Occurrence in Both Non-Insulin-Dependent and Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1984
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- The Dawn Phenomenon, an Early Morning Glucose Rise: Implications for Diabetic Intraday Blood Glucose VariationDiabetes Care, 1981
- Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitusDiabetologia, 1977
- Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell DefectScience, 1973